SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS
Clinical trials for SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS trials appear
Sign up with your email to follow new studies for SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a diabetes drug shield Teens' kidneys?
Disease control Recruiting nowThis study tests whether a daily pill called dapagliflozin (an SGLT2 inhibitor) can reduce protein leakage in the urine of teenagers aged 14–18 with mild chronic kidney disease. About 200 participants will receive either the drug or a placebo for six months. The goal is to see if…
Matched conditions: SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS
Phase: PHASE4 • Sponsor: Centenario Hospital Miguel Hidalgo • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
Could a common diabetes pill slow kidney decline in dialysis patients?
Disease control Recruiting nowThis study tests whether a daily 25 mg dose of empagliflozin, a drug typically used for diabetes, is safe and can help preserve the small amount of kidney function still present in people on peritoneal dialysis. About 20 adults with end-stage kidney disease who produce at least 2…
Matched conditions: SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 26, 2026 08:30 UTC